• Policy
• An additional purchase contract of pfizer tx has been signed
• by Kim, Jung-Ju Jan 7, 2022 06:06am

• Company
• Ahn to reduce generic price to counter Lee's hair loss reimb
• by Kim, Jin-Gu Jan 7, 2022 06:06am

• Policy
• Is the KRAS gene-targeted drug also released in Korea?
• by Lee, Tak-Sun Jan 6, 2022 06:09am

• Company
• New triple combo ‘Enerzair’ for asthma lands in 'Big 5'
• by Eo, Yun-Ho Jan 6, 2022 06:09am

• Product
• Lee’s pledge to reimburse hair loss drug creates buzz
• by Jung, Heung-Jun Jan 6, 2022 06:09am

• Policy
• There were no applications for Ultomiris·Soliris benefits
• by Lee, Hye-Kyung Jan 6, 2022 06:09am

• Policy
• Companies obtain generic for exclusivity in proportion
• by Lee, Tak-Sun Jan 6, 2022 06:08am

• Policy
• Request for non-reimbursed use of Pahtension in Loop's pts
• by Lee, Hye-Kyung Jan 6, 2022 06:08am

• Policy
• ‘Lowest-ever’ number of drugs approved in 4 years
• by Lee, Tak-Sun Jan 5, 2022 05:59am

• InterView
• There shouldn't be any patients who can't receive new drugs
• by Eo, Yun-Ho Jan 5, 2022 05:59am